Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: erythropoietin mimetics - BioRexis

Drug Profile

Research programme: erythropoietin mimetics - BioRexis

Alternative Names: EPO mimetic - BioRexis; EPO peptide mimetic - BioRexis; EPO receptor agonist peptide; Erythropoietin mimetics - BioRexis

Latest Information Update: 21 May 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioRexis Pharmaceutical Corporation
  • Class
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Anaemia

Most Recent Events

  • 21 Apr 2007 No development reported - Preclinical for Anaemia in USA (unspecified route)
  • 14 Jul 2004 The programme is available for licensing (http://www.biorexis.com)
  • 14 Jul 2004 Preclinical trials in Anaemia in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top